February 20, 2026 Teva’s Olanzapine Injectable for Schizophrenia Receives FDA Acceptance OR FDA Accepts Teva’s NDA for Extended-Release Olanzapine Injection OR Teva Submits New Schizophrenia Treatment – FDA Application Accepted
